Home/Filings/3/0001213900-15-008923
3//SEC Filing

SCIVANTA MEDICAL CORP 3

Accession 0001213900-15-008923

CIK 0001093285operating

Filed

Nov 18, 7:00 PM ET

Accepted

Nov 19, 8:18 PM ET

Size

13.9 KB

Accession

0001213900-15-008923

Insider Transaction Report

Form 3
Period: 2015-11-01
Holdings
  • 10% Convertible Debenture

    (indirect: See footnote)
    Exercise: $0.13From: 2016-02-12Exp: 2016-02-12Common Stock, par value $0.001 (384,615 underlying)
  • Warrant (right to buy common stock)

    (indirect: See footnote)
    Exercise: $0.13From: 2016-02-12Exp: 2019-02-12Common Stock, par value $0.001 (76,923 underlying)
Footnotes (3)
  • [F1]The $50,000 principal amount and accrued interest of this 10% Convertible Debenture (the "Debenture") is convertible into shares of Scivanta Medical Corporation (the "Company") common stock upon: (a) a Qualified Financing, as defined in the Debenture, at a conversion price equal to: (i) 80% of the per share price paid by the purchasers of the Company's common stock in the Qualified Financing; (ii) 80% of the per share conversion price of any instrument convertible into shares of the Company's common stock, if no shares of the Company's common stock are issued in the Qualified Financing; or (iii) $0.13, if no shares of the Company's common stock or instruments convertible into shares of the Company's common stock are issued in the Qualified Financing; (b) a Change in Control of the Company, as defined Debenture, at a conversion price of $0.13 per share; or (c) at the option of the holder, on the maturity date of the Debenture, at a conversion price of $0.13 per share.
  • [F2]Mr. Desouza is a member of Turn Two Investments, LLC ("Turn Two"). Mr. Desouza disclaims beneficial ownership of these shares except to the extent of his ownership in Turn Two.
  • [F3]The warrant provides the holder the right to purchase shares of the Company's common stock equal to 20% of the principal amount of the Debenture divided by: (a) 80% of the per share price paid by the purchasers of the Company's common stock in a Qualified Financing; (b) 80% of the per share conversion price of any instrument convertible into shares of the Company's common stock issued in a Qualified Financing, if no shares of the Company's common stock are issued in the Qualified Financing; or (c) $0.13, if no shares of the Company's common stock or no instruments convertible into shares of the Company's common stock are issued in a Qualified Financing or if a Qualified Financing is not consummated within one year from the warrant issuance date.

Issuer

SCIVANTA MEDICAL CORP

CIK 0001093285

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001093285

Filing Metadata

Form type
3
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 8:18 PM ET
Size
13.9 KB